This trial is testing a new cancer treatment that combines a drug called AFM24 with a drug called atezolizumab. The trial is open to people with certain types of advanced cancer who have tried other treatments that didn't work.
2 Primary · 7 Secondary · Reporting Duration: During cycle 1 (each cycle has 28 days)
105 Total Participants · 2 Treatment Groups
Primary Treatment: AFM24 · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: